arrow
M

Martina M. McGrath

Mass General Brigham
H指数:26
被引数:1,901

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prognostic Significance of Large Language Model-Extracted Clinical Features at admission for Heart Failure: Insights from DELIVER and PARAGON-HF

心衰入院时大型语言模型提取的临床特征预后意义:来自DELIVER和PARAGON-HF研究的见解

2026-05-210
PRE
Finerenone and eGFR Slope across Different Levels of Baseline Albuminuria and eGFR Insights from FINEARTS-HF

非奈利酮和eGFR斜率在不同基线白蛋白尿和eGFR水平下的差异:FINEARTS-HF研究启示

2025-11-010
PRE
Repetitive ischemic injuries to the kidneys result in lymph node fibrosis and impaired healing (vol 3, e120546, 2018)

反复发生的肾脏缺血性损伤会导致淋巴结纤维化和愈合障碍(vol 3, e120546, 2018)

2025-09-230
PRE
Angiotensin Receptor Neprilysin Inhibition and Cardiovascular Outcomes Across the Kidney Function Spectrum The PARAGON-HF Trial

血管紧张素受体脑啡肽酶抑制剂与全肾功能谱的心血管结局:PARAGON-HF试验

2025-01-010
PRE
Kidney and cardiac biomarkers and risk of adverse kidney outcomes in patients with type 2 diabetes and kidney disease, cardiovascular disease, or both

肾脏和心脏生物标志物以及2型糖尿病合并肾脏疾病、心血管疾病或两者兼具的患者发生不良肾脏结局的风险

2024-11-120
PRE
Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial
2024-02-018
OAAI
Sacubitril/valsartan compared to ramipril in high-risk post-myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: insight from the PARADISE MI trial

沙库比曲/缬沙坦与雷米普利在根据盐皮质激素受体拮抗剂使用分层的高危心肌梗死后患者中的比较: 来自PARADISE MI试验的见解

2023-11-292
OA
Initial Decline in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: Insights From DELIVER
2023-11-070
PRE
Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER
2023-02-2130
OAAI
Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction A Prespecified Analysis of the DELIVER Randomized Clinical Trial
2023-01-0156
OA
Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction A Participant-Level Pooled Analysis of DAPA-HF and DELIVER
2022-12-0127
OAAI
Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction:PARAGON-HF
2020-09-3039
OAAI